Jorge A R Salvador
Overview
Explore the profile of Jorge A R Salvador including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moura S, Marin S, Rufino I, Guedes R, Cascante M, Salvador J
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769100
A series of novel carnosic acid derivatives incorporating urea moieties at the C-20 position was synthesized and evaluated for their antiproliferative activity against the HCT116 colorectal cancer cell line. Most...
2.
Antoniuk O, Maranha A, Salvador J, Empadinhas N, Moreira V
Nat Prod Rep
. 2024 Oct;
41(12):1858-1894.
PMID: 39371026
Covering: 2013 to 2023In an era where antimicrobial resistance severely threatens our ability to treat infections, the discovery of new drugs that belong to different chemical classes and/or bear original...
3.
Coimbra J, Resende R, Custodio J, Salvador J, Santos A
J Alzheimers Dis
. 2024 Jun;
101(s1):S53-S78.
PMID: 38943390
Disease-modifying therapies (DMT) for Alzheimer's disease (AD) are highly longed-for. In this quest, anti-amyloid therapies take center stage supported by genetic facts that highlight an imbalance between production and clearance...
4.
Vicente A, Salvador J
MedComm (2020)
. 2024 Jun;
5(6):e575.
PMID: 38845697
Leukemia is a heterogeneous group of life-threatening malignant disorders of the hematopoietic system. Immunotherapy, radiotherapy, stem cell transplantation, targeted therapy, and chemotherapy are among the approved leukemia treatments. Unfortunately, therapeutic...
5.
Goncalves A, Matias M, Salvador J, Silvestre S
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338879
Bismuth compounds are considered relatively non-toxic, with their low solubility in aqueous solutions (e.g., biological fluids) being the major contributing factor to this property. Bismuth derivatives are widely used for...
6.
Fernandes P, Guedes R, Victor B, Salvador J, Guedes R
Front Chem
. 2024 Jan;
11:1322628.
PMID: 38260042
Acquired resistance to drugs that modulate specific protein functions, such as the human proteasome, presents a significant challenge in targeted therapies. This underscores the importance of devising new methodologies to...
7.
Pereira T, Abbasi M, Oliveira R, Guedes R, Salvador J, Arrais J
J Comput Aided Mol Des
. 2023 Oct;
37(12):791-806.
PMID: 37847342
In this work, we develop a method for generating targeted hit compounds by applying deep reinforcement learning and attention mechanisms to predict binding affinity against a biological target while considering...
8.
Carreira L, Oliveira R, Moreira V, Salvador J
Expert Opin Ther Targets
. 2023 Oct;
27(11):1043-1058.
PMID: 37789645
Introduction: Ubiquitin-specific protease 7 (USP7) also known as herpesvirus-associated ubiquitin-specific protease (HAUSP) is a well-characterized cysteine protease that belongs to the largest subfamily of deubiquitinating enzymes (DUBs). It is involved...
9.
Guedes R, Grilo J, Carvalho A, Fernandes P, Ressurreicao A, Brito V, et al.
Pharmaceuticals (Basel)
. 2023 Aug;
16(8).
PMID: 37631011
Cancer is a complex multifactorial disease whose pathophysiology involves multiple metabolic pathways, including the ubiquitin-proteasome system, for which several proteasome inhibitors have already been approved for clinical use. However, the...
10.
Vicente A, Salvador J
Expert Opin Ther Pat
. 2023 Jul;
33(6):397-420.
PMID: 37494069
Introduction: PROteolysis-TArgeting Chimeras (PROTACs) allow the selective degradation of a protein of interest (POI) by the ubiquitin-proteasome system (UPS). With this unique mechanism of action, the research and development of...